Overview
- 4 inspections across 4 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2021-09-17.
At a glance
Inspections
4
Sites
4
Observations
0
Career since
Mar 2018
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Janssen Pharmaceuticals Inc. | 17 Sep 2021 | Biologics | |
| Carolinas Cord Blood Bank | 2 Aug 2019 | Biologics | On file |
| GlaxoSmithKline Biologicals | 13 Nov 2018 | Biologics | On file |
| Baxalta US Inc. | 2 Mar 2018 | Biologics | On file |
Sites inspected
Janssen Pharmaceuticals Inc.Raritan, United States1 insp.
Carolinas Cord Blood BankDurham, United States1 insp.
GlaxoSmithKline BiologicalsSaint-Amand-Les-Eaux, France1 insp.
Baxalta US Inc.Social Circle, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Randa Melhem2 shared
Jacqueline M Diaz Albertini1 shared
Zhaohui Ye1 shared
David E Bailey1 shared
Graeme E Price1 shared
Jacqueline M Diaz Albert1 shared
Sukhanya Jayachandra1 shared
Thomas P Finn1 shared
Ekaterina Allen1 shared
Prabhu P Raju1 shared
Full investigator report
Get the verbatim findings behind Lily Y Koo's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site